Whether lithium inhibits glycogen synthase kinase (GSK)-3β activity in vivo in humans is still an open question

Related Experiment Video

Updated: Mar 17, 2026

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue
02:30

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue

Published on: October 24, 2025

256

Galila Agam1,2,3, Abed N Azab1,3,4

  • 1Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Bipolar Disorders
|July 22, 2016
PubMed
Abstract

No abstract available in PubMed .

Keywords:
bipolar disorderglycogen synthase kinase (GSK)-3βlithiumtherapeutic mechanism

More Related Videos

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.5K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K